drugset / Trial / NCT02971839
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.
Timeline
- Start
- 2016-12
- Primary completion
- 2017-08
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IVA | Unknown | — | — |
| Subject | deutivacaftor | Unknown | 20 mg | — |
| Subject | deutivacaftor | Unknown | 100 mg | — |
| Subject | deutivacaftor | Unknown | 150 mg | — |